CODX
Co-Diagnostics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.10
P/S
2.75
EV/EBITDA
0.30
DCF Value
$7.42
FCF Yield
-1741.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.3%
Operating Margin
-8058.8%
Net Margin
-7533.6%
ROE
-125.5%
ROA
-189.5%
ROIC
-221.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $263.9K | $-25.7M | $-16.54 |
| FY 2025 | $622.5K | $-46.9M | $-35.25 |
| Q3 2025 | $145.4K | $-5.9M | $-4.66 |
| Q2 2025 | $162.9K | $-7.7M | $-7.00 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.32
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.